Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) was the target of some unusual options trading activity on Wednesday. Stock traders bought 6,053 call options on the stock. This is an increase of 407% compared to the average daily volume of 1,195 call options.

Analysts Set New Price Targets

XENE has been the subject of a number of research reports. Royal Bank Of Canada lifted their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 4th. Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th. JPMorgan Chase & Co. increased their target price on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Wolfe Research initiated coverage on shares of Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, Needham & Company LLC raised their target price on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $55.50.

Insiders Place Their Bets

In related news, CEO Ian Mortimer sold 40,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the transaction, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $266,580. This trade represents a 86.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 65,205 shares of company stock valued at $2,919,762 in the last three months. 4.07% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC bought a new stake in shares of Xenon Pharmaceuticals during the fourth quarter valued at about $33,000. Blue Trust Inc. lifted its stake in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares during the period. Danske Bank A S bought a new position in shares of Xenon Pharmaceuticals in the third quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $43,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in Xenon Pharmaceuticals during the third quarter worth approximately $39,000. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Stock Performance

XENE traded down $1.31 on Wednesday, reaching $42.48. 254,232 shares of the company’s stock were exchanged, compared to its average volume of 944,770. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.99. The company’s 50 day moving average is $42.41 and its 200-day moving average is $41.14. The company has a market cap of $3.53 billion, a price-to-earnings ratio of -9.74 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the prior year, the firm earned ($0.84) earnings per share. Sell-side analysts forecast that Xenon Pharmaceuticals will post -3.1 EPS for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.